Stock Research: Prestige

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Prestige

NYSE:PBH US74112D1019
39
  • Value
    82
  • Growth
    27
  • Safety
    Safety
    34
  • Combined
    50
  • Sentiment
    37
  • 360° View
    360° View
    39
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Prestige Consumer Healthcare Inc. is a consumer healthcare products company. It operates in the consumer healthcare industry and its brands include Monistat, Summer’s Eve, BC, Goody's, Clear Eyes, and others. It operates in North America, Australia, and other international markets. In the last fiscal year, the company had a market cap of $3,699 million, profits of $634 million, revenue of $1,138 million, and 600 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 39 (better than 39% compared with alternatives), overall professional sentiment and financial characteristics for the stock Prestige are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Prestige. The only rank that is above average is the consolidated Safety Rank at 82, which means that the company has a financing structure that is safer than those of 82% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 34, which means that the share price of Prestige is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 27, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 37, which means that professional investors are more pessimistic about the stock than for 63% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
D.J. US Pharmaceutical
S&P MIDCAP
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
34 28 46 67
Growth
27 43 65 69
Safety
Safety
82 48 50 26
Sentiment
37 100 90 99
360° View
360° View
39 63 89 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
29 41 88 39
Opinions Change
6 97 50 50
Pro Holdings
n/a 94 60 96
Market Pulse
85 93 83 94
Sentiment
37 100 90 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
34 28 46 67
Growth
27 43 65 69
Safety Safety
82 48 50 26
Combined
50 23 62 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
59 45 56 68
Price vs. Earnings (P/E)
41 39 43 55
Price vs. Book (P/B)
47 41 43 64
Dividend Yield
1 1 1 1
Value
34 28 46 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
18 18 24 25
Profit Growth
38 39 100 65
Capital Growth
63 57 54 46
Stock Returns
37 69 55 97
Growth
27 43 65 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
56 38 32 34
Refinancing
47 28 31 19
Liquidity
77 70 72 60
Safety Safety
82 48 50 26

Similar Stocks

Discover high‑ranked alternatives to Prestige and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.